Application Value of Laparoscopic Roux-en-Y Gastric Bypass in Treating Obesity with Nonalcoholic Fatty Liver

Chu Xuehui,Qiu Chen,Shan Xiaodong,Deng Ling,Sun Xitai

DOI: https://doi.org/10.3877//cma.j.issn.2095-9605.2016.02.006

2016-01-01

Abstract:Objective To investigate the application value of laparoscopicRoux-en-Y gastric bypass (LRYGB) in treating obesity with nonalcoholic fatty liver disease.Methods Clinical data of 69 obese patients with nonalcoholic fatty liver disease undergoing LRYGB in Gulou Hospital Affiliated to Medical College of Nanjing University from November 2011 to November 2014 were analyzed retrospectively. The informed consents were obtained from all of the patients and the local ethical committee approval had been received. Among the 69 patients, 25 were males and 44 were females with an average age of (40±13) years old and an average body mass index of (37.9±6.5) kg/m2. Levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyltransferase (GGT), albumin, total cholesterol (TC), triglyceride (TG), fasting plasma glucose (FPG), fasting insulin (FIns), fasting plasma C-peptide (FCp) and results of liver ultrasound were tested before and at different time points after operation. Results of liver ultrasound were compared using Spearman rank correlation analysis, and other clinical indexes were compared using t test.Results Sixty-nine patients received LRYGB successfully. At 1 month after operation, BMI was (34±5) kg/m2, which was significantly lower than (38±7) kg/m2 before operation(t=3.863,P<0.05); TG was (1.8±0.7) mmol/L, which was significantly lower than (2.9±1.2) mmol/L(t=6.577,P<0.05) before operation; ALT was (47±26) U/L, which was significantly lower than (71±48) U/L before operation(t=3.652, P<0.05); FPG was (5.1±1.1) mmol/L, which was significantly lower than (8.0±2.8) mmol/L(t=8.008, P<0.05); and FIns was (16±12) mIU/L, which was also significantly lower than (32±20) mIU/L(t=5.698, P<0.05). At 6 months after operation, 29 patients got complete remission of fatty liver; 23 patients were diagnosed with mild fatty liver, 17 patients with moderate fatty liver, and no patient with severe fatty liver. These severity ranks of fatty liver were significantly milder than that before operation (0 normal, 39 mild, 23 moderate and 7 severe) (χ2=25.777,P<0.05).Conclusion LRYGB can not only treat obesity, but also improve fatty liver significantly, which may be related to lipid metabolism and insulin resistance.